GURIOLI, GIULIA
 Distribuzione geografica
Continente #
AS - Asia 297
NA - Nord America 127
EU - Europa 114
SA - Sud America 17
AF - Africa 13
Totale 568
Nazione #
US - Stati Uniti d'America 122
SG - Singapore 114
CN - Cina 94
HK - Hong Kong 38
IT - Italia 35
DE - Germania 24
NL - Olanda 23
VN - Vietnam 18
KR - Corea 17
BR - Brasile 13
FI - Finlandia 9
FR - Francia 7
IN - India 6
SC - Seychelles 6
GB - Regno Unito 5
AR - Argentina 3
AT - Austria 3
ID - Indonesia 3
IE - Irlanda 3
MX - Messico 3
CA - Canada 2
CI - Costa d'Avorio 2
JP - Giappone 2
RU - Federazione Russa 2
TG - Togo 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
CO - Colombia 1
ES - Italia 1
IR - Iran 1
PL - Polonia 1
SA - Arabia Saudita 1
SE - Svezia 1
TN - Tunisia 1
TR - Turchia 1
Totale 568
Città #
Singapore 73
Ashburn 40
Hong Kong 38
Hefei 36
Santa Clara 18
Seoul 17
Beijing 14
Ho Chi Minh City 10
Munich 10
Boardman 9
Bologna 9
Falkenstein 9
Los Angeles 9
Helsinki 6
Fort Worth 5
Hanoi 5
Bengaluru 3
Buffalo 3
Dublin 3
Harbin 3
Redondo Beach 3
Rome 3
Abidjan 2
Brooklyn 2
Dallas 2
Genoa 2
Jakarta 2
Lappeenranta 2
Lomé 2
London 2
Milan 2
Modena 2
Princeton 2
Rezzato 2
Shanghai 2
Shaoxing 2
Shijiazhuang 2
Springfield 2
São Paulo 2
Tokyo 2
Udine 2
Amsterdam 1
Ankara 1
Apodaca 1
Baoding 1
Bordeaux 1
Burzaco 1
Bühl 1
Cachoeiro de Itapemirim 1
Catania 1
Chandler 1
Chengdu 1
Curitiba 1
Denver 1
Des Moines 1
Durban 1
Düsseldorf 1
Florianópolis 1
Gaomi 1
Genzano di Roma 1
Groningen 1
Guangzhou 1
Iztacalco 1
Jeddah 1
João Pessoa 1
Juneau 1
Lang Son 1
Lauterbourg 1
Lomas de Zamora 1
Maricá 1
Medford 1
Mexico City 1
Monza 1
Nanjing 1
Nuremberg 1
Passo Fundo 1
Ponte San Pietro 1
Porto Alegre 1
Prineville 1
Quanzhou 1
Richmond 1
Rio de Janeiro 1
Salt Lake City 1
Salvador 1
San Francisco 1
Santo André 1
Seattle 1
Shenzhen 1
Southend 1
São Bernardo do Campo 1
Tampa 1
Tongling 1
Toronto 1
Tunis 1
Turku 1
Vienna 1
Vĩnh Tường 1
Wroclaw 1
Wuhan 1
Yubileyny 1
Totale 423
Nome #
Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer 123
Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients 102
Uma experiência inclusiva com a plataforma MIROR e a LIS-Língua italiana de sinais em uma escola de ensino fundamenal I 69
Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide 63
Reclassification of good-risk seminoma: Prognostic factors, novel biomarkers and implications for clinical management 54
Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide 48
Endometriosis and endometrial cancer: A propensity score-adjusted real-world data study 40
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide 39
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 35
Circulating tumor DNA fraction (ctDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer (mCRPC) 14
Totale 587
Categoria #
all - tutte 1.832
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.832


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20229 0 0 0 0 0 0 2 1 1 0 3 2
2022/20239 1 1 0 1 0 1 1 1 2 0 1 0
2023/202415 0 1 0 0 0 0 0 0 10 1 3 0
2024/2025291 13 32 28 28 28 17 13 24 2 30 20 56
2025/2026263 59 50 39 41 57 17 0 0 0 0 0 0
Totale 587